CEP-18770
| Brand Name: | |
| Generic Name: | |
| Code Name: | CEP-18770 |
| Company: | Cephalon |
| FDA Clinical Phase: | preclinical |
Description:
CEP-18770 is a boronic-acid based proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous cells. Animal studies showed that CEP-18770 demonstrated superior activity to Velcade (bortezomib), and it caused fewer side effects during treatment.
Clinical Trials:
Currently, there are not yet any clinical trials studying CEP-18770 for multiple myeloma.
Updated November 14, 2009
Related Articles:
- ASH 2008 – Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
- Research Shows Velcade’s Possible Mechanism of Action
- New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
- ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
- Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
Leave a comment